SUMMARY
Sodium nitroprusside-enhanced cardiopulmonary resuscitation has shown superior resuscitation rates and neurologic outcomes in large animal models supporting the need for a randomized human clinical trial. This study is the first to show nonselective pulmonary vasodilation as a potential mechanism for the hemodynamic benefits. The pulmonary shunting that is created requires increased oxygen treatment, but the overall improvement in blood flow increases minute oxygen delivery to tissues. In this context, hypoxemia is an important safety endpoint and a 100% oxygen ventilation strategy may be necessary for the first human approximately only 5% to 10% achieve neurologically intact survival (3) . Approximately one-third of patients experiencing out-of-hospital cardiac arrests present with ventricular tachycardia/ventricular fibrillation (VF) (4) . Epinephrine is a commonly used vasoconstrictor for standard cardiopulmonary resuscitation (CPR) in and out of hospital protocols in congruence with current American Heart Association guidelines; however, no study to date has shown improvement in long-term outcomes (5) .
A new method of CPR has been proposed that significantly increases forward blood flow and overall patient outcomes (6) (7) (8) (9) (10) (11) . Sodium nitroprussideenhanced CPR (SNPeCPR) is the combination of 3 basic components: 1) SNP, a potent vasodilator, to decrease peripheral vascular resistance in tandem with abdominal binding (7, 8) to decrease descending aorta runoff and redirect blood flow to the vital organs;
2) an impedance threshold device; and 3) active compression/decompression CPR to actively increase venous return (11) . Together, these components act synergistically to increase coronary and cerebral perfusion during CPR (12) .
Previous studies of SNPeCPR have indicated an improved carotid blood flow (CBF), end-tidal CO 2 , and return of spontaneous circulation (ROSC) rates and short-term 24-to 48-h survival rates with favorable neurologic function compared to those of standard CPR (8, (12) (13) (14) (15) (16) (17) (18) ). There appears to be a vital timepoint after which hemodynamic decompensation during extended standard CPR is inevitable and irreversible (19) . The use of SNPeCPR shifts the survival curve, increasing a valuable window for which to resuscitate the patient (8, (12) (13) (14) (15) (16) (17) (18) . This shift of the metabolic wall represents an invaluable clinical application of patient selection for furthered resuscitation efforts. As more patients are treated following prolonged periods of CPR, and with increasing access to enhanced CPR (eCPR) and veno-arterial extracorporeal membrane oxygenation therapies, providing a superior advanced cardiac life support (ACLS) and CPR method will become critical (20) . Before the first clinical trial for SNPeCPR can be performed, safety must be further evaluated.
We sought to investigate the blood flow effects of SNPeCPR during prolonged CPR and to understand the predominant mechanism of its action. We hypothesized that the predominant effect of SNPeCPR is indiscriminate profound pulmonary vasodilation. As such, the ability to maintain adequate oxygenation with SNPeCPR was the main focus of this study.
METHODS
All studies were performed with approval from the Institutional Animal Care and Use Committee. Animal and data monitoring have been described thoroughly in previous studies (7, 22) . Intramuscular ketamine and xylazine was provided as sedation (5 ml of 100 mg/ml dose and 1 to 3 mg/kg, respectively). This was followed by inhaled isoflurane at a dose of 1% to 1.4%. Endo- is outlined in Figure 1 . VF was electrically induced in forts were terminated if no ROSC was achieved. Animals with ROSC were followed for a total of 60 min, at which point they were sacrificed.
VENTILATION, OXYGEN DELIVERY STRATEGY, AND ALVEOLAR-ARTERIAL GRADIENT CALCULATION.
All animals were ventilated as stated above at 10 breaths per minute with 10 ml/kg tidal volume. Room air was used during preparation and at the initiation of the VF. During CPR, oxygen was increased only if a saturation of <90% was observed (as indicated by standard formula at the next ABG reading:
As such, the study sought to evaluate both the effect of SNPeCPR on pulmonary vasodilation but also the level of FiO 2 support needed to maintain adequate tissue oxygenation over time. ABGs. Arterial and venous blood gas results over the entire 30 min of prolonged CPR are shown in Table 2 .
SNPeCPR showed a significant decrease in PaO 2 levels after SNP delivery which coincided with an increased A-a gradient. Increasing the FiO 2 led to adequate PaO 2 and overall tissue oxygen delivery while the increase Table 1 ).
A coronary perfusion pressure of <15 mm Hg has been negatively associated with achieving ROSC and successful defibrillation (23, 24) . SNPeCPR animals fell below this threshold later than compared to control animals (Table 1, Figure 4) . As it can be seen in the groups. CPR is a low-flow state, and the impact of high arterial oxygen levels on outcomes is poorly understood. In our study, although the SNPeCPR group had lower PaO 2 and relative hypoxemia, tissue oxygen consumption was improved due to the increase in CPR-generated blood flow; therefore, there and, as our study shows, a significant and profound pulmonary circulation vasodilation. SNPeCPR has been shown to increase ROSC rates and short-term neurologically intact survival rates in multiple studies and is ready for a phase 1 clinical trial.
TRANSLATIONAL OUTLOOK: The current study identifies hypoxemia as a potential safety issue during ventilation with room air and suggests that SNPeCPR should be tested in humans with an FiO 2 >0.5. Despite relative hypoxemia with lower FiO 2 ventilation, SNPeCPR oxygen delivery to the tissues is increased due to higher blood flow generation.
